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Abstract
Background: Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera
of patients with malignant diseases.
Methods:  We investigated the course of nucleosomal DNA, thymidine kinase, lactate
dehydrogenase and leukocytes in sera of 25 patients with acute myeloid leukemia during the first
cycle of induction chemotherapy and tested their power to distinguish between patients with
complete remission and those with no remission.
Results: Almost all patients showed strongly decreasing levels of nucleosomal DNA during the
first week, in some cases after initial peaks. In overall analysis of variance, DNA levels could clearly
distinguish between patients with complete remission, who had higher DNA values, and those with
insufficient response (p = 0.017). The area under the curve of DNA values of days 2–4 after start
of therapy (AUC 2–4) discriminated between both groups with a sensitivity of 56% at a specificity
of 100%. Further, pretherapeutic levels and AUC 2–4 of nucleosomal DNA correlated significantly
with blast reduction after 16 days. A tendency to higher levels in patients with complete response
was also found for thymidine kinase, lactate dehydrogenase and leukocytes, however the difference
did not reach the level of significance (p = 0.542, p = 0.260, and p = 0.144, respectively).
Conclusion: Our results indicate that nucleosomal DNA fragments are valuable markers for the
early prediction of therapeutic efficacy in patients with acute myeloid leukemia.
Background
The incidence of acute myeloid leukemia (AML) has
remained stable over the last decades and has averaged
between 1998 and 2002 at about 3.8 per 100,000 persons
and year. The age-adjusted incidence rates showed a dis-
tinct difference between patients under 65 years with 1.8
per 100,000 and those over 65 years with 17.9 per
100,000 [1]. With regard to the treatment of AML, a stand-
ardized procedure has been established including induc-
tion chemotherapy to eliminate the blasts and to achieve
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remission followed by a consolidation therapy to stabilize
the remission status [2,3]. Unfortunately the rate of com-
plete remission after induction therapy, particularly in
older patients, ranges only between 38% and 62% and
could not been improved during the recent years. Younger
patients often receive more intensive treatment such as
double induction therapies including TAD/TAD (TAD:
cytarabine, daunorubicine, 6-thioguanine) or TAD/HAM
(HAM: cytarabine, mitoxantrone) and complete remis-
sion is achieved in 65% to 71% [3,4] of these cases.
Besides age there are several prognostic markers for AML
patients that are used in clinical routine: Cytogenetics
contain the most important prognostic information [5-7],
as does the blast number in the bone marrow: High
amounts of bone marrow blasts before therapy are associ-
ated with adverse outcome [8] as well as incomplete elim-
ination during the course of chemotherapy [9]. Lactate
dehydrogenase (LDH) and leukocyte number are further
markers which are relevant for prognosis [6,8]. However,
additional and more precise markers are warranted to esti-
mate the therapy response as early as possible.
Chemotherapeutic agents induce apoptotic cell death in
target cells like cells of tumorous tissue [10-13]. The apop-
totic process by cytoxic drugs is started by direct damage
of DNA, interference in the cell cycle [10,14], or by the
activation of apoptotic receptors such as Fas/Apo1/CD95
[11,12]. Subsequently a cascade of enzymes is activated
[15] which results in the degradation of the cellular struc-
ture and cleavage of the chromatin into mono- and olig-
nucleosomes by various caspases and nucleases [16-18].
These nucleosomes are packed into apoptotic bodies and
are engulfed by neighbouring cells and macrophages.
However a substantial part is released into circulation par-
ticularly in high rates of cell death [19,20]. Thus, nucleo-
somal DNA levels in plasma and serum can be correlated
with the extent of cell death at a specific time point. Meas-
urement of circulating DNA fragments can be performed
in plasma and serum by various methods including real
time PCR and ELISA [21,22].
Healthy individuals and patients with benign diseases
show lower levels of nucleosomal DNA in their circula-
tion than persons with malignant diseases [22-27]. In pre-
vious investigations typical kinetics of nucleosomal DNA
could be observed during radio- and chemotherapy [28].
Patients with solid tumors receiving chemotherapy
showed a rapid increase of nucleosomal DNA levels 24–
72 hours after the application followed by a decrease to
reach the basal levels after about one week [25,27]. With
regard to the early prediction of therapeutic efficacy,
patients with lung cancer with insufficient response to
chemotherapy showed a higher increase and a less effec-
tive decrease of nucleosomal DNA values during the first
week than those with good response to therapy [29].
In contrast to solid tumors, malignant leukemic cells are
always present in the bone marrow and/or in the blood
circulation. Thus the release of nucleosomal DNA into
serum or plasma is facilitated and is independent of the
blood supply of the tumor.
The present study was undertaken to investigate the
courses of nucleosomal DNA fragments, thymidine
kinase, lactate dehydrogenase and leukocytes in patients
with AML during chemotherapy. The main purpose was to
explore whether the courses of nucleosomal DNA in AML
patients differ from those of patients with solid tumors
and whether they could early and reliably predict the




Twenty five consecutive patients with acute myeloid
leukemia (AML) were included in our study, among them
23 patients with de novo AML and 2 patients with relapse
of the disease.
The de novo AML patients received induction chemother-
apy with one or two cycles of the TAD and/or HAM-pro-
tocols. TAD chemotherapy, which generally was applied
as first induction course, contained 100 mg/m2 cytarabine
(days 1, 2 and 3 through 8 every twelve hours), 60 mg/m2
daunorubicin (days 3–5) and 100 mg/m2 6-thioguanine
(days 3–9 every twelve hours). HAM was given as second
cycle or as first and second induction course consisting of
3 g/m2 (<60 years) or 1 g/m2 (>60 years) cytarabine (days
1–3 every twelve hours) and 10 mg/m2 mitoxantrone
(days 3, 4). The two patients with relapsed AML received
a cytarabine + daunorubicin combination and the F-S-
Hai-protocol, respectively. Characteristics of the patients
are summarized in table 1. [Table 1]
The study was approved by the local ethics committee.
Before inclusion in the study, written informed consent
was given by all patients.
Estimation of treatment efficacy
With regard to therapy response, it was differentiated
between patients with complete remission (n = 18) and
those with failure (n = 7) of therapy. According to the cri-
teria of the German AML Cooperative Group, complete
remission was defined by bone marrow cytology per-
formed after induction therapy, where there were less than
5% blasts and normal hematopoiesis of all cell lines in the
bone marrow, and more than 1,500 neutrophils and
100,000 platelets per microliter in peripheral blood for atBMC Cancer 2006, 6:143 http://www.biomedcentral.com/1471-2407/6/143
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least four weeks. Patients with insufficient decline of the
blasts, death earlier than 7 days after the end of the first
induction cycle or death because of the treatment-induced
bone marrow hypoplasia after chemotherapy were catego-
rized as therapeutic failure [4].
Measurement of blood parameters
Blood samples were taken before the first application of
chemotherapy (day 1) and then daily in the morning dur-
ing the whole cycle. Preanalytical handling of serum sam-
ples was performed as described earlier [22]: Blood
samples were centrifuged at 3000 g for 15 minutes, treated
with 10 mM EDTA immediately after the centrifugation
and stored at -80°C. Subsequently, the samples were
thawed and nucleosomes were measured in batches com-
bining all samples of a patient to minimize the interassay
variability by the Cell Death Detection-ELISAplus of Roche
Diagnostics. The samples were placed into a microtiter-
plate and, additionally, a mixture of anti-histone-antibod-
ies, anti-DNA-antibodies and a buffer solution: Anti-
histone-antibodies bound to the histone component and
were fixed to the microtiterplate whereas anti-DNA-anti-
bodies labelled with peroxidase recognized the DNA com-
ponent of the nucleosomes. After a washing step, the
peroxidase retained in the immunocomplex reacted with
2,2'-azino-di(3-ethylbenzthiazoline-sulfonat) substrate
and the amount of nucleosomes was determined quanti-
tatively by spectrophotometrical analysis in ng/mL DNA.
In parallel, thymidine kinase (TK) was measured by a radi-
oimmunoassay (Immunotech), leukocytes and lactate
dehydrogenase (LDH) were determined daily by routine
methods (Coulter LH 750 Analyzer, Beckman, and Olym-
pus AU 2700, Olympus, respectively) on the day of sam-
ple collection.
Statistics
Correlations between nucleosomal DNA fragments and
leukocytes on the one hand and blast number on the
other hand were calculated by Spearman rank correlation.
An overall analysis of variance was performed to test the
general dependency of the concentrations of DNA frag-
ments, thymidine kinase, lactate dehydrogenase and leu-
kocytes upon response to therapy (complete response
versus no response) and on time before (day 1) and after
start of chemotherapy (day 2 – day 8), respectively. In case
of a significant overall effect of therapy, the effects of sin-
gle days were tested, too. Additionally, the interaction
between therapy response and time was investigated. This
was done using SAS Procedure MIXED, which can take
into account dependencies of repeated values of the same
patient. For this analysis data were used as logarithms.
Using Wilcoxon test, the marker levels, their changes from
pretherapeutic value (day 1) to day 2 and the area under
the curve of nucleosomal DNA values from day 2 to 4 after
start of therapy (AUC 2–4) were analyzed on their dis-
criminative power between the two response groups. To
calculate AUC 2–4, the concentrations of days 2, 3 and 4
were mandatory.
For all evaluations, a p-value <0.05 was considered statis-
tically significant. All calculations were performed by soft-
Table 1: Characteristics of the patients investigated
Median Range














Trisomy 8 1 (4.0)
Trisomy 11 1 (4.0)
Trisomy 21, Isochrom X 1 (4.0)
Mosaic 46XX, 45X0 1 (4.0)
Inversion 16 2 (4.0)
Inversion 3 1 (4.0)
Inversion 3, Monosomy 7 1 (4.0)
Pericentric Inversion 4 1 (4.0)
Translocation (2;5) 1 (4.0)
Translocation (8;21) 1 (4.0)
Translocation (15;17) 1 (4.0)
Immunophenotype
MPO, CD13, CD33 15 (60.0)
MPO, CD13, CD33, CD 14 1 (4.0)
MPO, CD13, CD33, CD3, CD7, Cd2, TdT 1 (4.0)






Relapse therapy 2 (8.0)
Therapy response
Complete remission 18 (72.0)
Non-Responders 7 (28.0)BMC Cancer 2006, 6:143 http://www.biomedcentral.com/1471-2407/6/143
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ware of SAS (version 8.2, SAS Institute Inc., Cary, NC,
USA).
Results
Eighteen patients out of twenty five showed a complete
remission in the peripheral blood and bone marrow after
induction or relapse chemotherapy. The remaining seven
AML patients showed no or only insufficient response to
therapy and four of them died during the bone marrow
hypoplasia after treatment.
During the first week of chemotherapy, a decrease of
nucleosomal DNA levels was observed in almost all
patients. In some patients, DNA concentrations increased
temporarily immediately after start of the therapy. 50% of
the patients in the remission group (9 of 18) showed an
early increase at day 2, whereas values decreased immedi-
ately in most non-responsive patients (6 of 7). However,
there was no significant difference between both groups
concerning the percentual changes from day 1 to 2 (p =
0.259). [Table 2]
Generally, higher values were measured in patients who
achieved complete remission compared with those who
showed an insufficient therapy response [Figure 1]. In
overall analysis of variance, levels of nucleosomal DNA
fragments were dependent on both variables being ther-
apy response (p = 0.017) and time after start of chemo-
therapy (p = 0.023), respectively. No interaction was
observed between therapy response and time (p = 0.495).
In detailed analysis, significantly higher values of nucleo-
somal DNA were found for the days 2 and 4 (p = 0.014
and p = 0.022, respectively); day 3 was of borderline sig-
nificance (p = 0.051). If these values were integrated in the
area under the curve of days 2–4 (AUC 2–4) of circulating
nucleosomal DNA, a significant difference between
patients with complete response and those who were not
responsive to therapy was observed (p = 0.042). By AUC
2–4, both groups could be separated with a sensitivity of
56% and a specificity of 100% at a cutoff level of 150 ng/
mL*d [Figure 2].
Thymidine kinase levels increased steeply from day 1 to
day 4 followed by a rapid decrease. In analysis of variance,
thymidine kinase levels were only dependent on time
after start of chemotherapy (p = 0.001), but not on ther-
apy response (p = 0.750), though the median levels at sin-
gle days were higher in patients with complete remission.
There was also no interaction between therapy response
and time (p = 0.360). [Table 2]
Levels of lactate dehydrogenase were neither dependent
on time after start of chemotherapy (p = 0.161), nor on
therapy response (p = 0.251). There was also no interac-
tion between therapy response and time (p = 0.359).
[Table 2]
Leukocyte levels remained almost constant until day 3 in
patients with complete response whereas they decreased
immediately after start of chemotherapy in most of the
patients with insufficient response. In analysis of variance,
leukocytes showed a clear dependency on time after start
of chemotherapy (p < 0.001), but not on therapy response
(p = 0.193). There was also no interaction between ther-
apy response and time (p = 0.914). However, with respect
to the percentual changes from day 1 to 2, a borderline
significant difference was observed (p = 0.059). [Table 2]
Investigating the immediate effect of therapy on markers
concentrations, a positive correlation was identified for
the levels of nucleosomal DNA fragments at day 2 with
leukocytes at day 2 (r = 0.54; p = 0.009) as well as with the
increase of leukocytes from day 1 to 2 (r = 0.58; p =
0.010). This correlation was maintained in the subgroup
of patients with complete remission (r = 0.76; p = 0.001
and r = 0.56; p = 0.049, respectively), but not in the sub-
group of patients with insufficient response (r = 0.20; p =
0.704 and r = -0.31; p = 0.544, respectively).
Because cytogenetics and immunophenotype were very
heterogeneous, correlations with therapy response were
not performed. The bone marrow blast numbers at days 1
and 16 as well as their percentual changes were compara-
ble in both response groups and could not discriminate
between patients with complete remission and those with
no response to therapy. [Table 2]
No correlation was observed between pretherapeutic
nucleosomal DNA levels and bone marrow blast number
(r = 0.08; p = 0.722). However, pretherapeutic nucleo-
somal DNA levels correlated inversely with bone marrow
blast number after 16 days (r = -0.55; p = 0.012) and with
the relative reduction of blast number from day 1 to 16 (r
= 0.58; p = 0.007). Similarly, the area under the curve of
days 2–4 (AUC 2–4) of circulating nucleosomal DNA
reflecting the immediate effect of therapy correlated with
the reduction of blast number from day 1 to 16 (r = 0.49;
p = 0.041).
Discussion
Treatment of acute myeloid leukemia aims to achieve
complete remission. In contrast to solid tumors which
show a response to therapy when there is a reduction of
the tumor mass, patients with AML are considered suffi-
ciently treated only when there are no blasts in the periph-
eral blood or less than 5% blasts in the bone marrow. The
AML patients receive systemic chemotherapy partitioned
to at least two parts: the induction therapy aiming at effec-
tive reduction of malignant cells and the consolidationBMC Cancer 2006, 6:143 http://www.biomedcentral.com/1471-2407/6/143
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therapy consisting of chemotherapy with or without
autologous or allogeneic stem-cell transplantation to pre-
vent relapse of leukemia [2,3].
Antileukemic drugs like cytarabine in combination with
daunorubicine and 6-thioguanine (TAD), or with mitox-
antrone (HAM) cause DNA damage or inhibit DNA syn-
thesis and, thus, kill tumor cells mainly by apoptosis [30].
The activation of caspases-3 and caspases-8 was already
detected 12–24 hours after the application of the chemo-
therapeutic drugs [31,32]. Also morphologically, increas-
ing numbers of apoptotic cells were observed after
application of the cytotoxic therapy; for example mitox-
antrone induced early apoptosis and showed a high rate
of cell death of blast cells during the initial 24 hours [14].
Another study reported cytarabine to induce cytotoxicity
and to reduce the viability of bone marrow blasts by two
thirds 24 hours and almost completely 96 hours after
application of the drug [32].
At high rates of spontaneous and treatment-induced
apoptosis, tumor cell-free DNA was measured in blood
circulation by immunoassays or by real time PCR [21,22].
A plentitude of studies report higher levels of cell-free
DNA in plasma and serum of cancer patients than in
healthy individuals regarding almost all types of solid
tumors, leukemia or lymphoma [23-27,33-37]. During
the course of anticancer therapy in patients with solid
tumors, levels of cell free DNA decreased in patients who
showed effective response to therapy whereas they
increased or remained constant in those patients with sta-
ble or progressive disease or at time of relapse [23,38-40].
The same effects were observed in nasopharyngeal carci-
nomas and lymphomas during radiotherapy or chemo-
therapy concerning EBV-DNA [41-43].
Most DNA in circulation is supposed to be organized in
nucleosomes as complexes of DNA and histones [20,44-
46]. As protein bound particles, they seem to be better
conserved against rapid digestion by serum and plasma
endonucleases [47]. Methods for the detection of cell free
DNA and nucleosomal DNA have shown good correla-
tions with regard to single values as well as to serial meas-
urements [48]. During the initial phase of chemotherapy,
levels of nucleosomal DNA showed a rapid increase in the
blood of patients with solid tumors already 24 – 72 hours
after application followed by a decrease during the first
week [25,27,29]. In various solid tumors, the kinetics of
Distribution of nucleosomal DNA in patients with complete remission and no remission during the first week of induction  therapy (-- = medians) Figure 1
Distribution of nucleosomal DNA in patients with complete remission and no remission during the first week of induction 
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the nucleosomal DNA levels during chemo- and radio-
therapy correlated with the therapy response: Declining
baseline values determined before the various cycles were
associated with effective treatment, whereas stable or
increasing values were observed in patients with insuffi-
cient response [25,28,29]. In addition, the early changes
of nucleosomal DNA levels have proved to be valuable for
the early prediction of the therapeutic efficacy in patients
with lung cancer: Patients with remission showed only
minor increases of nucleosomal DNA followed by rapid
and complete decreases during the first week of chemo-
therapy. Patients with progressive disease, however, had
stronger increases and less complete decreases of nucleo-
somal DNA. Thus, the resulting area under the curve from
day 1 to 8 was able to predict the later treatment response
[29]. In pancreatic cancer during radiotherapy too,
response was anticipated by changes of nucleosomal DNA
levels already during the first days of the therapy [50].
In this study, we investigated the concentration of nucleo-
somal DNA fragments in patients with AML daily during
the first week of induction therapy. The serum values
decreased significantly in all patients during this time
frame. However, in patients who later achieved complete
remission, levels remained constant or increased only
slightly on day 2 followed by a rapid and continuous
decrease to approximately one third of the pretherapeutic
level. Generally, patients with response tended to have
higher nucleosomal DNA levels than non-responding
patients. These changes of serum nucleosomal DNA in
AML patients contrasted clearly to our earlier results in
patients with solid tumors: In patients with AML, higher
nucleosomal DNA levels were detected in those who were
responsive to therapy, whereas in patients with solid
tumors they were higher in the non-responsive group.
These controverse observations might be explained by dif-
ferent pathophysiological backgrounds of the tumor enti-
ties:
Patients with solid tumors treated with systemic therapies
often have aggressive tumor types in already advanced
stages with high tumor load. The high levels of circulating
The area under the curve of nucleosomal DNA values of days 2–4 of induction therapy (AUC 2–4) discriminates between  patients with complete remission and those with no remission Figure 2
The area under the curve of nucleosomal DNA values of days 2–4 of induction therapy (AUC 2–4) discriminates between 
patients with complete remission and those with no remission. A) AUC 2–4 of nucleosomal DNA is significantly larger for 
patients with complete response (CR ■) than for those not responsive (no CR ●) to therapy (p = 0.042). Here, median levels 
of days 1 to 4 and the respective AUC 2–4 are shown for both response groups. B) Distribution of AUC 2–4 levels of nucleo-
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nucleosomal DNA particularly in those patients who are
non-responsive to antitumor therapy might be due to a) a
higher rate of cellular turnover before and during therapy
corresponding with a higher release of nucleosomal DNA,
b) a higher rate of dysfunctional cells easily killed by cyto-
toxic therapies, c) a better blood supply of the tumor tis-
Table 2: Correlation of nucleosomal DNA, thymidine kinase, lactate dehydrogenase, leukocytes and bone marrow blast number with 
response to therapy
Complete response No response P-value
N Median Range N Median Range
Nucleosomal DNA fragments (ng/mL)
Effect of therapy response on nucleosomal DNA 0.017
Effect of time after start of chemotherapy (days) on nucleosomal DNA 0.023
Interaction between therapy response and time 0.495
Day 1 (before therapy) 15 65.2 22.3 – 267.1 7 30.3 16.0 – 90.9 0.104
Day 2 18 86.4 21.7 – 807.7 6 25.7 17.7 – 128.1 0.014
Day 3 18 63.5 11.4 – 657.8 6 21.2 12.0 – 50.3 0.051
Day 4 16 44.6 9.7 – 613.8 5 14.9 12.0 – 36.0 0.022
Day 5 16 36.0 12.6 – 154.4 6 31.5 12.0 – 86.4 0.530
Day 6/7/8 18 24.0 9.2 – 2031.2 6 16.6 9.2 – 38.3 0.060
Day 2 – Day 1 % 15 2.5 -76 – 305 6 -16.5 -35.3 – 40.9 0.259
Thymidine kinase (U/L)
Effect of therapy response on thymidine kinase 0.750
Effect of time after start of chemotherapy (days) on thymidine kinase 0.001
Interaction between therapy response and time 0.360
Day 1 (before therapy) 15 50.6 6 – 603 7 40.9 10 – 1095
Day 2 17 88.9 1 – 727 6 54.1 22 – 127
Day 3 18 183.0 5 – 1789 6 121.2 47 – 998
Day 4 15 302.0 25 – 1158 5 85.6 58 – 772
Day 5 14 194.5 22 – 1161 6 193.5 57 – 758
Day 6/7/8 18 175.5 29 – 1040 7 146.0 36 – 414
Day 2 – Day 1 % 14 21.9 -90 – 626 6 50.2 -63 – 110 0.970
Lactate dehydrogenase (U/L)
Effect of therapy response on LDH 0.251
Effect of time after start of chemotherapy (days) on LDH 0.161
Interaction between therapy response and time 0.359
Day 1 (before therapy) 10 346 120 – 672 5 326 202 – 427
Day 2 10 373 177 – 1603 4 237 147 – 391
Day 3 11 361 204 – 876 3 278 183 – 282
Day 4 9 533 153 – 1068 3 285 217 – 330
Day 5 9 380 182 – 1405 3 318 218 – 440
Day 6/7/8 12 304 174 – 1087 4 261 232 – 336
Leukocytes (G/L)
Effect of therapy response on leukocytes 0.193
Effect of time after start of chemotherapy (days) on leukocytes <0.001
Interaction between therapy response and time 0.914
Day 1 (before therapy) 14 3.4 1.2 – 52.5 7 3.4 0.7 – 37.4
Day 2 16 3.7 0.5 – 43.1 6 2.2 0.6 – 30.3
Day 3 16 3.8 0.5 – 23.0 5 1.6 0.9 – 17.0
Day 4 13 2.1 0.6 – 22.3 3 1.7 0.9 – 5.4
Day 5 11 1.7 0.7 – 3.4 3 0.8 0.7 – 1.5
Day 6/7/8 13 0.9 0.5 – 21.6 3 0.9 0.5 – 1.1
Day 2 – Day 1 % 13 -1.4 -61 – 79 6 -35.4 -54 – -14.3 0.059
Bone Marrow Blast Number (%)
Day 1 (before therapy) 18 72 7 – 90 7 74 25 – 93 0.880
Day 16 17 0 0 – 6 6 4 0 – 72 0.385
Day 1 – Day 16 % 17 100 14 – 100 6 88 3 – 100 0.385BMC Cancer 2006, 6:143 http://www.biomedcentral.com/1471-2407/6/143
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sue facilitating the transition of nucleosomal DNA into
blood circulation, and d) a defective clearance system of
circulating nucleosomal DNA. Though in both, respon-
sive and non-responsive patients with solid tumors, a con-
siderable number of tumor cells will die during therapy,
the effective elimination of nucleosomal DNA in blood
and already before transition into circulation is supposed
to be associated with a more functional immune system in
patients with less advanced tumors and better therapy
response.
In AML, malignant blasts are present in the blood circula-
tion and bone marrow and constitute there the target for
chemotherapeutic agents. This effect was shown by flow
immunocytometric methods that detected high numbers
of apoptotic peripheral blood lymphocytes and blasts in
the circulation shortly after application of cytotoxic chem-
otherapy depending on the type and dose of the drugs
[14,51]. High rates of apoptotic cells and, thus, high levels
of nucleosomal DNA, passing directly over into blood cir-
culation, correspond with sufficient response to the
respective treatment whereas low levels correlate with rel-
ative resistance of target cells to undergo apoptosis. As
nucleosomal DNA is already released 12–24 hours after
the apoptotic event [52], and as they are removed rapidly
from circulation under physiological conditions, the early
increase followed by a rapid decrease during the induc-
tion therapy might reflect the effective elimination of
leukemic cells [53,54].
As well as malignant cells, other rapidly proliferating cells
are also damaged by cytotoxic drugs resulting in side
effects such as myelotoxicity including anemia, leukope-
nia and thrombopenia as well as mucositis and gastroin-
testinal symptoms. In addition, specific side effects are
known to be caused by some drugs such as pulmonary
toxicity for cytarabine and cardiotoxicity for daunorubi-
cine and mitoxantrone. Besides leukemic cells, therefore,
also other normal or inflammatory cells might contribute
to the release of nucleosomal DNA.
To specify the information given by circulating nucleo-
somal DNA, we compared it with the number of leuko-
cytes and already established proliferation and cell death
markers such as thymidine kinase and lactate dehydroge-
nase, which are already in clinical use for patients with
leukemia or lymphomas. In recent studies, AML patients
with a high pretherapeutic thymidine kinase activity have
often achieved an adequate blast clearance after the first
induction cycle [55]. Additionally in agreement with this
data, levels of thymidine kinase tended to be higher in
patients with complete remission pretherapeutically as
well as during the whole first cycle in our study. Similarly,
we observed somewhat higher lactate dehydrogenase con-
centrations in patients with complete remission during
chemotherapy. Though there was strong dependency of
thymidine kinase and LDH concentrations on time after
start of chemotherapy, there was no significant associa-
tion with the response to therapy for both markers.
Remarkably however, the levels of nucleosomal DNA
fragments were clearly dependent on both time after start
of chemotherapy and therapy response, respectively,
whereas treatment efficacy was not related to time. The
most significant differences between both response
groups were found in particular for nucleosomal DNA lev-
els at the very initial phase of the therapy. This observa-
tion reflects the constantly high DNA concentrations
during days 1 to 4 in patients with complete remission in
contrast to the early declining levels in those patients with
insufficient response. An elegant parameter to integrate
the information given at the single days is the area under
the curve of days 2–4 (AUC 2–4) of nucleosomal DNA. As
the pretherapeutic value was not considered in this varia-
ble, AUC 2–4 reflected the immediate therapy effect on
the release of nucleosomal DNA. Consistently with the
results of the single days, AUC 2–4 of nucleosomal DNA
could discriminate between the groups of patients with
complete response and those who were not responsive to
therapy (p = 0.042). In particular, AUC 2–4 enabled the
prediction of favourable therapy response with a sensitiv-
ity of 56% at a specificity of 100%.
High values in responsive patients and early decreases in
non-responsive patients were observed for leukocytes,
too. Although there was no significant difference in the
absolute leukocyte counts between both groups, the rela-
tive changes from day 1 to 2 were of borderline signifi-
cance (p = 0.059).
Most notably, the correlation analysis revealed an interre-
lationship of leukocytes on day 2 or changes of leukocyte
numbers during the course of therapy with the concentra-
tions of DNA fragments in serum (p = 0.009 and p =
0.010, respectively). This observation suggests that leuko-
cytes might be an important source or at least a stimulator
for the release of DNA fragments into blood or they might
prevent their elimination from circulation. As this correla-
tion was particularly relevant for patients with complete
remission but not for those with failure to therapy, it
seems reasonable that the higher levels of circulating
nucleosomal DNA fragments are mainly the result of
effective blast reduction. This hypothesis is further
strengthened by our observation that the pretherapeutic
levels and the AUC 2–4 of nucleosomal DNA, reflecting
the immediate effect of therapy, were related to the per-
centual reduction of bone marrow blast number from
days 1 to 16.BMC Cancer 2006, 6:143 http://www.biomedcentral.com/1471-2407/6/143
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The correlation of further parameters which are used in
clinical routine for diagnostic or prognostic purposes,
such as cytogenetics and immunophenotype, with nucle-
osomal DNA and therapy response was not possible in
our setting as the patient number was limited and the het-
erogeneity of these markers was considerable. However, it
would be valuable to include these markers together with
the kinetics of circulating nucleosomal DNA fragments in
prospective trials to elucidate their potential additive
power for the early prediction of therapy response.
Conclusion
Our results indicate that, in AML patients, the changes of
nucleosomal DNA during the initial phase of induction
chemotherapy are valuable markers for the early estima-
tion of therapy response and should be validated in fur-
ther prospective trials.
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